ArticleFrontiers in endocrinology2025
Serum microRNAs as peripheral markers of primary aldosteronism.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging methods for subtype differentiation in primary aldosteronism.Journal of internal medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary aldosteronism (PA) is the principal cause of secondary hypertension; it leads to significantly elevated cardiovascular morbidity and mortality, but only a fraction of its cases ever get detected, partially due to diagnostic procedures that are difficult to perform and to interpret. More straightforward diagnostic methods are needed. Lateralized, or unilateral PA (uPA), is best treated by surgery. Bilateral PA (bPA) is treated medically. Aim: The aim of our study was to explore microRNA (miRNA) in peripheral blood as markers of PA, uPA and bPA. Methods: In groups of subjects with primary hypertension (HT, n = 11), bPA (n = 12), and uPA (n = 16), peripheral serum was used for isolation of total RNA, library preparation, and NGS sequencing to achieve a comparative analysis of miRNA expression. Five-fold cross-validation support vector machine learning (ML) models were employed to search for miRNA that could be used as markers of PA and its forms. Results: In our cohort of patients, the discovered combinations of miRNAs could, with a high level of accuracy, sensitivity, and specificity, characterize the difference between HT and PA, as well as between a combined group of HT + bPA vs. uPA. The differentiating parameters were moderately good for comparison of bPA vs. uPA. Conclusion: Within our patient cohort, and using ML, the study identified distinctly different miRNA profiles between HT and PA, as well as between bPA and uPA. Further validation studies may lead to the emergence of a new tool for clinical diagnostics of PA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.